A Phase 3 double-blind, placebo-controlled study clinical trial to determine effect of enobosarm in older (> 60 years) age patients who have obesity or who are overweight and who are eligible for treatment with GLP-1 RA (semaglutide and/or tirzepatide)
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Enobosarm (Primary) ; Semaglutide (Primary) ; Tirzepatide (Primary)
- Indications Obesity; Overweight
- Focus Registrational; Therapeutic Use
- 03 Feb 2025 New trial record
- 27 Jan 2025 According to a Veru media release, company is planning to meet FDA, to discuss regulatory path and the design of anticipated Phase 3 clinical program.